345 related articles for article (PubMed ID: 27062086)
1. Quinoxaline-Based Scaffolds Targeting Tyrosine Kinases and Their Potential Anticancer Activity.
El Newahie AM; Ismail NS; Abou El Ella DA; Abouzid KA
Arch Pharm (Weinheim); 2016 May; 349(5):309-26. PubMed ID: 27062086
[TBL] [Abstract][Full Text] [Related]
2. Molecular modeling studies and synthesis of novel quinoxaline derivatives with potential anticancer activity as inhibitors of c-Met kinase.
Abbas HA; Al-Marhabi AR; Eissa SI; Ammar YA
Bioorg Med Chem; 2015 Oct; 23(20):6560-72. PubMed ID: 26420384
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and structure-activity relationship of novel quinoxaline derivatives as cancer chemopreventive agent by inhibition of tyrosine kinase receptor.
Galal SA; Abdelsamie AS; Soliman SM; Mortier J; Wolber G; Ali MM; Tokuda H; Suzuki N; Lida A; Ramadan RA; El Diwani HI
Eur J Med Chem; 2013 Nov; 69():115-24. PubMed ID: 24013411
[TBL] [Abstract][Full Text] [Related]
4. An insight into medicinal chemistry of anticancer quinoxalines.
Kaushal T; Srivastava G; Sharma A; Singh Negi A
Bioorg Med Chem; 2019 Jan; 27(1):16-35. PubMed ID: 30502116
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of 3-vinyl-quinoxalin-2(1H)-one derivatives as novel antitumor inhibitors of FGFR1.
Liu Z; Yu S; Chen D; Shen G; Wang Y; Hou L; Lin D; Zhang J; Ye F
Drug Des Devel Ther; 2016; 10():1489-500. PubMed ID: 27217720
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2.
Guillon J; Le Borgne M; Rimbault C; Moreau S; Savrimoutou S; Pinaud N; Baratin S; Marchivie M; Roche S; Bollacke A; Pecci A; Alvarez L; Desplat V; Jose J
Eur J Med Chem; 2013 Jul; 65():205-22. PubMed ID: 23711832
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of the antiproliferative activity of novel isoindolo[2,1-a]quinoxaline and indolo[1,2-a]quinoxaline derivatives.
Desplat V; Moreau S; Belisle-Fabre S; Thiolat D; Uranga J; Lucas R; de Moor L; Massip S; Jarry C; Mossalayi DM; Sonnet P; Déléris G; Guillon J
J Enzyme Inhib Med Chem; 2011 Oct; 26(5):657-67. PubMed ID: 21250818
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of type-II VEGFR-2 inhibitors based on quinoxaline scaffold.
Shahin MI; Abou El Ella DA; Ismail NS; Abouzid KA
Bioorg Chem; 2014 Oct; 56():16-26. PubMed ID: 24922538
[TBL] [Abstract][Full Text] [Related]
9. Multisubstituted quinoxalines and pyrido[2,3-d]pyrimidines: synthesis and SAR study as tyrosine kinase c-Met inhibitors.
Wu K; Ai J; Liu Q; Chen T; Zhao A; Peng X; Wang Y; Ji Y; Yao Q; Xu Y; Geng M; Zhang A
Bioorg Med Chem Lett; 2012 Oct; 22(20):6368-72. PubMed ID: 22985853
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design of novel quinoxaline-2-carboxylic acids and analogues as Pim-1 inhibitors.
Oyallon B; Brachet-Botineau M; Logé C; Bonnet P; Souab M; Robert T; Ruchaud S; Bach S; Berthelot P; Gouilleux F; Viaud-Massuard MC; Denevault-Sabourin C
Eur J Med Chem; 2018 Jun; 154():101-109. PubMed ID: 29778892
[TBL] [Abstract][Full Text] [Related]
11. Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.
Kim KH; Maderna A; Schnute ME; Hegen M; Mohan S; Miyashiro J; Lin L; Li E; Keegan S; Lussier J; Wrocklage C; Nickerson-Nutter CL; Wittwer AJ; Soutter H; Caspers N; Han S; Kurumbail R; Dunussi-Joannopoulos K; Douhan J; Wissner A
Bioorg Med Chem Lett; 2011 Nov; 21(21):6258-63. PubMed ID: 21958547
[TBL] [Abstract][Full Text] [Related]
12. Unravelling the Selectivity of 6,7-Dimethyl Quinoxaline Analogs for Kinase Inhibition: An Insight towards the Development of Alzheimer's Therapeutics.
Kumar Jain A; Gupta A; Karthikeyan C; Trivedi P; Dutt Konar A
Chem Biodivers; 2021 Nov; 18(11):e2100364. PubMed ID: 34486216
[TBL] [Abstract][Full Text] [Related]
13. Quinoxaline Nucleus: A Promising Scaffold in Anti-cancer Drug Discovery.
Pinheiro AC; Mendonça Nogueira TC; de Souza MV
Anticancer Agents Med Chem; 2016; 16(10):1339-52. PubMed ID: 27349448
[TBL] [Abstract][Full Text] [Related]
14. Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline and Pyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitors.
Patinote C; Bou Karroum N; Moarbess G; Deleuze-Masquefa C; Hadj-Kaddour K; Cuq P; Diab-Assaf M; Kassab I; Bonnet PA
Eur J Med Chem; 2017 Sep; 138():909-919. PubMed ID: 28750313
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of (E)-2-(2-arylhydrazinyl)quinoxalines, a promising and potent new class of anticancer agents.
Rodrigues FA; Bomfim Ida S; Cavalcanti BC; Pessoa Cdo Ó; Wardell JL; Wardell SM; Pinheiro AC; Kaiser CR; Nogueira TC; Low JN; Gomes LR; de Souza MV
Bioorg Med Chem Lett; 2014 Feb; 24(3):934-9. PubMed ID: 24398294
[TBL] [Abstract][Full Text] [Related]
16. Pyridinylquinoxalines and pyridinylpyridopyrazines as lead compounds for novel p38 alpha mitogen-activated protein kinase inhibitors.
Koch P; Jahns H; Schattel V; Goettert M; Laufer S
J Med Chem; 2010 Feb; 53(3):1128-37. PubMed ID: 20078117
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and evaluation of the cytotoxic activity of novel ethyl 4-[4-(4-substitutedpiperidin-1-yl)]benzyl-phenylpyrrolo[1,2-a]quinoxaline-carboxylate derivatives in myeloid and lymphoid leukemia cell lines.
Desplat V; Vincenzi M; Lucas R; Moreau S; Savrimoutou S; Pinaud N; Lesbordes J; Peyrilles E; Marchivie M; Routier S; Sonnet P; Rossi F; Ronga L; Guillon J
Eur J Med Chem; 2016 May; 113():214-27. PubMed ID: 26945110
[TBL] [Abstract][Full Text] [Related]
18. From simple quinoxalines to potent oxazolo[5,4-f]quinoxaline inhibitors of glycogen-synthase kinase 3 (GSK3).
Lassagne F; Duguépéroux C; Roca C; Perez C; Martinez A; Baratte B; Robert T; Ruchaud S; Bach S; Erb W; Roisnel T; Mongin F
Org Biomol Chem; 2019 Dec; 18(1):154-162. PubMed ID: 31803883
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of the antiproliferative activity of novel pyrrolo[1,2-a]quinoxaline derivatives, potential inhibitors of Akt kinase. Part II.
Desplat V; Moreau S; Gay A; Fabre SB; Thiolat D; Massip S; Macky G; Godde F; Mossalayi D; Jarry C; Guillon J
J Enzyme Inhib Med Chem; 2010 Apr; 25(2):204-15. PubMed ID: 20222763
[TBL] [Abstract][Full Text] [Related]
20. New Quinoxaline Derivatives as Dual Pim-1/2 Kinase Inhibitors: Design, Synthesis and Biological Evaluation.
Oyallon B; Brachet-Botineau M; Logé C; Robert T; Bach S; Ibrahim S; Raoul W; Croix C; Berthelot P; Guillon J; Pinaud N; Gouilleux F; Viaud-Massuard MC; Denevault-Sabourin C
Molecules; 2021 Feb; 26(4):. PubMed ID: 33562106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
